X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-08-31 | CAMP | Camp4 Therapeutics Corp | Gold Kelly | CFO | P - Purchase | $3.96 | +10,000 | 86,467 | +13% | +$39,600 | ||||||
| D | 2026-09-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $25.76 | -5,787 | 9,110 | -39% | -$149,072 | |||||
2026-08-31 | GNLX | Genelux Corp | Cappello Joseph | Chief Technical Officer | S - Sale | $2.74 | -10,257 | 318,480 | -3% | -$28,112 | ||||||
2026-08-31 | GNLX | Genelux Corp | Zindrick Thomas | Pres, CEO | S - Sale | $2.67 | -34,463 | 1,226,427 | -3% | -$91,899 | ||||||
2026-08-31 | GNLX | Genelux Corp | Yu Yong | Chief Scientific Officer | S - Sale | $2.75 | -9,683 | 258,688 | -4% | -$26,658 | ||||||
2026-09-01 | ANTX | An2 Therapeutics, Inc. | Fitzpatrick Margaret M | Dir | P - Purchase | $5.53 | +2,098 | 10,708 | +24% | +$11,602 | ||||||
| D | 2026-08-28 | CDT | Cdt Equity Inc. | Regan Andrew | CEO | S - Sale+OE | $0.00 | -290 | 5,699,306 | 0% | -$0 | |||||
| M | 2026-08-31 | TENX | Tenax Therapeutics, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.79 | +770,333 | 5,624,151 | +16% | +$1,381,750 | |||||
2026-09-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $250.13 | -6,000 | 351,875 | -2% | -$1,500,780 | ||||||
2026-09-01 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Chief Accounting Officer | S - Sale | $2.02 | -19 | 23,782 | 0% | -$38 | ||||||
| D | 2026-09-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $514.09 | -9,500 | 668,728 | -1% | -$4,883,839 | |||||
2026-08-31 | OCUL | Ocular Therapeutix, Inc | Notman Donald | COO | S - Sale | $10.24 | -1,099 | 366,529 | 0% | -$11,254 | ||||||
| M | 2025-05-30 | EMMA | Emmaus Life Sciences, Inc. | Lee Willis C | CEO | P - Purchase | $0.03 | +530,767 | 1,326,485 | +67% | +$18,126 | |||||
2026-09-02 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +3,000 | 9,387,256 | 0% | +$147 | ||||||
| D | 2026-08-31 | QNRX | Quoin Pharmaceuticals, Ltd. | Carter Denise P. | COO | P - Purchase | $4.88 | +20,490 | 37,709 | +119% | +$99,991 | |||||
| D | 2026-08-31 | QNRX | Quoin Pharmaceuticals, Ltd. | Myers Michael | CEO | P - Purchase | $4.88 | +20,490 | 37,713 | +119% | +$99,991 | |||||
| D | 2026-08-31 | QNRX | Quoin Pharmaceuticals, Ltd. | Lawlor Sally Bridget | CFO | P - Purchase | $4.88 | +10,244 | 10,684 | >999% | +$49,991 | |||||
| D | 2026-08-31 | QNRX | Quoin Pharmaceuticals, Ltd. | Culverwell Anthony James | Dir | P - Purchase | $4.88 | +6,146 | 40,364 | +18% | +$29,992 | |||||
| D | 2026-08-28 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $35.77 | -200,000 | 1,599,154 | -11% | -$7,153,393 | |||||
| D | 2026-09-01 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $46.99 | -9,000 | 65,389 | -12% | -$422,874 | |||||
| D | 2026-09-01 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | COO | S - Sale+OE | $91.82 | -5,000 | 236,384 | -2% | -$459,101 | |||||
| D | 2026-09-01 | ORKA | Oruka Therapeutics, Inc. | Klein Lawrence Otto | CEO | S - Sale+OE | $91.83 | -75,000 | 925,580 | -7% | -$6,887,484 | |||||
2026-09-01 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $8.49 | -15,000 | 1,664,208 | -1% | -$127,308 | ||||||
2026-09-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $8.49 | -16,666 | 1,127,796 | -1% | -$141,434 | ||||||
2026-09-01 | XERS | Xeris Biopharma Holdings, Inc. | Pieper Steven | See Remarks | S - Sale | $8.50 | -5,000 | 1,356,053 | 0% | -$42,500 | ||||||
2026-08-31 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale | $72.80 | -2,850 | 171,843 | -2% | -$207,480 | ||||||
| D | 2026-08-31 | NBP | Novabridge Biosciences | Xu Cong Claire | EVP, Clinical Development | S - Sale+OE | $0.79 | -3,282 | 304,201 | -1% | -$2,593 | |||||
2026-09-01 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Dir | S - Sale | $5.86 | -15,000 | 62,065 | -19% | -$87,966 | ||||||
| D | 2026-09-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $25.47 | -1,452 | 117,227 | -1% | -$36,982 | |||||
2026-09-01 | CYTK | Cytokinetics Inc | Parshall B Lynne | Dir | S - Sale | $71.48 | -5,000 | 10,784 | -32% | -$357,400 | ||||||
| DM | 2026-08-28 | OMER | Omeros Corp | Cancelmo Peter B | VP, GC | S - Sale+OE | $18.59 | -50,000 | 200 | -100% | -$929,668 | |||||
| D | 2026-08-28 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $20.00 | -679 | 51,776 | -1% | -$13,580 | |||||
| D | 2026-08-31 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $511.09 | -9,500 | 668,728 | -1% | -$4,855,312 | |||||
| D | 2026-08-31 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale+OE | $105.46 | -62,774 | 114,024 | -36% | -$6,619,913 | |||||
| M | 2026-08-26 | MAIA | Maia Biotechnology, Inc. | Guerrero Ramiro | Dir | P - Purchase | $1.38 | +133,790 | 735,701 | +22% | +$184,103 | |||||
2026-08-31 | IMNN | Imunon, Inc. | Eylward Susan | GC, Corp Sec | S - Sale | $1.56 | -2,525 | 2,896 | -47% | -$3,950 | ||||||
| DM | 2026-08-27 | CMMB | Chemomab Therapeutics Ltd. | Cohen Neil Harris | Dir | S - Sale+OE | $2.83 | -2,304 | 33,000 | -7% | -$6,516 | |||||
2026-08-28 | XENE | Xenon Pharmaceuticals Inc. | Kenney Christopher John | Chief Medical Officer | S - Sale | $60.25 | -7,068 | 2 | -100% | -$425,829 | ||||||
| D | 2026-08-27 | JAZZ | Jazz Pharmaceuticals Plc | Iannone Robert | EVP, Global Head of R, D, CMO | S - Sale+OE | $249.70 | -76,921 | 65,686 | -54% | -$19,207,098 | |||||
| M | 2026-08-27 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.P. | 10% | S - Sale | $7.08 | -86,914 | 4,231,434 | -2% | -$615,777 | |||||
| M | 2026-08-27 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $7.08 | -86,914 | 4,231,434 | -2% | -$615,777 | |||||
| M | 2026-08-28 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $69.19 | +40,330 | 540,217 | +8% | +$2,790,326 | |||||
2026-08-27 | CAMP | Camp4 Therapeutics Corp | Schwab Andrew J. | Dir | S - Sale | $4.04 | -400,000 | 5,277,216 | -7% | -$1,616,000 | ||||||
| D | 2026-08-27 | COGT | Cogent Biosciences, Inc. | Morris Arlene | Dir | S - Sale+OE | $37.12 | -45,510 | 0 | -100% | -$1,689,493 | |||||
| D | 2026-08-31 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $70.24 | -10,000 | 58,555 | -15% | -$702,400 | |||||
| D | 2026-08-31 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $70.24 | -7,500 | 381,986 | -2% | -$526,800 | |||||
| D | 2026-08-28 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $517.51 | -9,500 | 668,728 | -1% | -$4,916,363 | |||||
2026-08-27 | VRXA | Veraxa Biotech AG - Post De-Spac | Baumann Oliver Rolf | Dir | P - Purchase | $1.50 | +50,000 | 5,773,618 | +1% | +$75,000 | ||||||
2026-08-27 | VRXA | Veraxa Biotech AG - Post De-Spac | Antz Christoph Rudiger | CEO | P - Purchase | $1.53 | +5,000 | 5,000 | New | +$7,650 | ||||||
| AD | 2026-08-28 | ETON | Eton Pharmaceuticals, Inc. | Maier Paul V | Dir | S - Sale+OE | $59.07 | -50,000 | 72,245 | -41% | -$2,953,572 | |||||
2026-08-31 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +3,500 | 9,384,256 | 0% | +$172 | ||||||
2026-08-27 | TNXP | Tonix Pharmaceuticals Holding Corp. | Lederman Seth | CEO | P - Purchase | $13.79 | +2,000 | 31,007 | +7% | +$27,580 | ||||||
2026-08-26 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | S - Sale | $1.56 | -2,000 | 127,777 | -2% | -$3,116 | ||||||
| A | 2026-04-14 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | P - Purchase | $1.01 | +110,388 | 129,777 | +569% | +$110,965 | |||||
| A | 2026-04-14 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | P - Purchase | $1.01 | +110,388 | 129,777 | +569% | +$110,965 | |||||
2026-08-28 | BIVI | Biovie Inc. | Palumbo Joseph M | Chief Medical Officer | P - Purchase | $2.16 | +4,843 | 6,036 | +406% | +$10,461 | ||||||
2026-08-28 | BIVI | Biovie Inc. | Chappell Amy Suzon | Dir | P - Purchase | $2.16 | +727 | 727 | New | +$1,570 | ||||||
2026-08-28 | BIVI | Biovie Inc. | Kim Joanne Wendy | CFO | P - Purchase | $2.18 | +2,500 | 3,441 | +266% | +$5,450 | ||||||
2026-08-27 | BIVI | Biovie Inc. | Do Cuong V | Pres, CEO | P - Purchase | $2.08 | +15,210 | 16,117 | >999% | +$31,637 | ||||||
2026-08-26 | PGEN | Precigen, Inc. | Kindler Jeffrey B | Dir | S - Sale | $7.44 | -185,000 | 17,100 | -92% | -$1,376,400 | ||||||
| AD | 2026-08-26 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale+OE | $111.39 | -4,090 | 11,486 | -26% | -$455,567 | |||||
| AD | 2026-08-25 | MNPR | Monopar Therapeutics | Anderson Raymond | Dir | S - Sale+OE | $111.98 | -3,142 | 5,373 | -37% | -$351,835 | |||||
| D | 2026-08-27 | ARQT | Arcutis Biotherapeutics, Inc. | Curran Terrie | Dir | S - Sale+OE | $25.03 | -38,200 | 23,526 | -62% | -$956,123 | |||||
| M | 2026-08-26 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $72.26 | -25,000 | 1,499,860 | -2% | -$1,806,509 | |||||
| D | 2026-08-28 | ETON | Eton Pharmaceuticals, Inc. | Maier Paul V | Dir | S - Sale+OE | $59.07 | -50,000 | 59,745 | -46% | -$2,953,572 | |||||
| DM | 2026-08-26 | OMER | Omeros Corp | Hanish Arnold C | Dir | S - Sale+OE | $18.81 | -15,000 | 12,400 | -55% | -$282,094 | |||||
| D | 2026-08-27 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $522.57 | -9,500 | 668,728 | -1% | -$4,964,376 | |||||
2026-08-26 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $13.96 | -300 | 141,002 | 0% | -$4,188 | ||||||
| D | 2026-08-26 | CORT | Corcept Therapeutics Inc | Park Kimberly | Dir | S - Sale+OE | $122.55 | -26,685 | 0 | -100% | -$3,270,169 | |||||
2026-08-26 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | S - Sale | $2.97 | -18,300 | 2,840,635 | -1% | -$54,351 | ||||||
| D | 2026-08-26 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale+OE | $13.69 | -77,000 | 69,828 | -52% | -$1,053,814 | |||||
| D | 2026-08-26 | MNPR | Monopar Therapeutics | Rioux Patrice | Acting Chief Medical Officer | S - Sale+OE | $111.26 | -1 | 5,065 | 0% | -$111 | |||||
2026-08-26 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale | $111.39 | -4,090 | 7,396 | -36% | -$455,567 | ||||||
2026-08-25 | MNPR | Monopar Therapeutics | Anderson Raymond | Dir | S - Sale | $111.77 | -3,142 | 23,751 | -12% | -$351,189 | ||||||
2026-08-25 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $380.00 | -280 | 1,286,449 | 0% | -$106,400 | ||||||
| D | 2026-08-25 | ABT | Abbott Laboratories | Ford Robert B | COB, CEO | S - Sale+OE | $115.85 | -398,832 | 522,664 | -43% | -$46,204,798 | |||||
| D | 2026-08-26 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $517.28 | -9,500 | 668,728 | -1% | -$4,914,190 | |||||
2026-08-26 | CYPH | Cypherpunk Technologies Inc. | Dietz Thomas John | Dir | S - Sale | $1.72 | -20,000 | 132,500 | -13% | -$34,400 | ||||||
| D | 2026-08-25 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $125.58 | -30,955 | 119,472 | -21% | -$3,887,320 | |||||
2026-08-25 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO | S - Sale | $2.21 | -14,036 | 2,615,911 | -1% | -$30,969 | ||||||
2026-08-25 | QTTB | Q32 Bio Inc. | Morrison Jodie Pope | CEO | S - Sale | $16.56 | -9,845 | 343,259 | -3% | -$163,033 | ||||||
2026-08-25 | QTTB | Q32 Bio Inc. | Kalowski Lee | CFO, Pres | S - Sale | $16.56 | -3,972 | 138,471 | -3% | -$65,776 | ||||||
2026-08-25 | QTTB | Q32 Bio Inc. | Violette Shelia M. | Chief Scientific Officer | S - Sale | $16.56 | -2,798 | 164,048 | -2% | -$46,335 | ||||||
2026-08-27 | INDV | Indivior Pharmaceuticals, Inc. | Anderson Woodrow D | Chief Accounting Officer | P - Purchase | $35.69 | +1,500 | 27,638 | +6% | +$53,535 | ||||||
| M | 2026-08-24 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $7.36 | -62,714 | 4,318,348 | -1% | -$461,546 | |||||
| M | 2026-08-24 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.P. | 10% | S - Sale | $7.36 | -62,714 | 4,318,348 | -1% | -$461,546 | |||||
| DM | 2026-08-24 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $83.10 | -9,096 | 54,324 | -14% | -$755,852 | |||||
2026-08-25 | ANIP | Ani Pharmaceuticals Inc | Lalwani Nikhil | Pres, CEO | S - Sale | $74.30 | -5,400 | 344,489 | -2% | -$401,220 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Kaiser Peter | Chief Development Officer | S - Sale | $10.77 | -3,035 | 264,378 | -1% | -$32,687 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Nayak Sanjay | Chief Strategy Officer | S - Sale | $10.78 | -1,897 | 326,898 | -1% | -$20,450 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Heier Jeffrey S. | Chief Scientific Officer | S - Sale | $10.78 | -3,296 | 318,326 | -1% | -$35,531 | ||||||
2026-08-24 | OCUL | Ocular Therapeutix, Inc | Dugel Pravin | See Remarks | S - Sale | $10.77 | -21,649 | 3,270,332 | -1% | -$233,160 | ||||||
2026-08-24 | CAMP | Camp4 Therapeutics Corp | Schwab Andrew J. | Dir | S - Sale | $4.50 | -10 | 5,677,216 | 0% | -$45 | ||||||
| D | 2026-08-25 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $517.71 | -9,500 | 668,728 | -1% | -$4,918,273 | |||||
| M | 2026-08-24 | ANL | Adlai Nortye Group Ltd. | Ye Xiaofeng | CFO | S - Sale | $14.11 | -11,667 | 147,757 | -7% | -$164,635 | |||||
2026-08-25 | BMY | Bristol Myers Squibb Co | Holzer Phil M | SVP, Controller | S - Sale | $67.50 | -500 | 16,862 | -3% | -$33,750 | ||||||
2026-08-25 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $49.57 | -18,921 | 569,645 | -3% | -$937,957 | ||||||
| M | 2026-08-24 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Chief Development Officer | S - Sale | $50.47 | -50,160 | 195,862 | -20% | -$2,531,582 | |||||
| M | 2026-08-24 | PRE | Prenetics Global Ltd | Rosin Brian J | CFO of IM8 (US) LLC | P - Purchase | $21.55 | +23,100 | 23,100 | New | +$497,700 | |||||
2026-08-24 | MAIA | Maia Biotechnology, Inc. | Guerrero Ramiro | Dir | P - Purchase | $1.33 | +1,794 | 601,911 | 0% | +$2,386 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |